Group 1 - The company, Hutchison China MediTech Limited (和黄医药), announced a meeting scheduled for October 31, 2025, in Shanghai to share its latest research and development progress [2] - During the event, Dr. Shi Ming, the Executive Vice President and Chief Medical Officer, will present the company's R&D strategy and vision, focusing on the antibody-drug conjugate (ATTC) platform and its first candidate drug HMPL-A251 [2] - The meeting will also cover updates on the later-stage R&D pipeline [2] Group 2 - The stock performance of Hutchison China MediTech Limited shows a recent increase of 11.20% [1] - The trading volume during the day reached 73,000 shares [1] - The stock price fluctuated between 22.26 and 28.10 during the trading session [1]
和黄医药将于10月31日介绍最新研发进展